ASND vs EXEL
Ascendis Pharma A/S and Exelixis, Inc., both Healthcare
Ascendis Pharma A/S is the larger company at $15B against $13B. Over the past year EXEL returned +50% against +32% for ASND.
| Figure | ASND | EXEL |
|---|---|---|
| Last close | $250 | $56.07 |
| Market cap | $15B | $13B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 18.6 |
| 1-year return | +32% | +50% |
| 5-year return | +108% | +225% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Ascendis Pharma A/S
Revenue of $248M in Q4 2025, net income null.
Exelixis, Inc.
Revenue of $611M in Q1 2026, net income $210M. Its largest reported line is Product Gross, 87% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.